Immunic Inc has raised $65 million from a public share offering to advance its pipeline of small molecule therapies for chronic inflammatory and autoimmune diseases. The offering consists of warrants to purchase stock in the company which can be exercised at different periods up until 3 June 2030. It closed on 3 June. Immunic could receive up to an additional $130 million if the warrants are exercised in full for cash. The financing was co-led by BVF Partners and Coastlands Capital with Leerink Partners as the bookrunner.
